ACB $1.430 (1.42%)

ACNNF $0.030 (0%)

AERO $3.210 (0%)

ALEAF $0.050 (-14.97%)

AMMJ $0.048 (12.81%)

APHA $15.380 (0%)

ARNA $99.990 (0%)

ATT:CNX $0.080 (0%)

AUSA:CNX $0.065 (0%)

AUSAF $0.050 (0%)

AVXL $11.060 (-0.98%)

BAMM:CNX $0.130 (0%)

BBM:CNX $0.030 (-14.29%)

BBRRF $0.027 (-3.27%)

Warning: Undefined array key 0 in /home/tech420/public_html/wp-content/themes/tech420/inc/shortcodes/stocks.php on line 51

Warning: Undefined array key 0 in /home/tech420/public_html/wp-content/themes/tech420/inc/shortcodes/stocks.php on line 52

BE:CNX $0.005 (0%)

BIO:CNX $0.013 (0%)

BLIS:CNX $0.315 (0%)

BLO:CNX $0.395 (2.6%)

BLOZF $0.308 (2.5%)

BUDZ $0.100 (-9.09%)

CADMF $0.052 (0%)

CALI:CNX $0.085 (13.33%)

CANN $0.230 (-2.13%)

CARA $9.060 (-6.69%)

CBWTF $0.062 (0.16%)

CGC $2.540 (-0.97%)

CGRW $0.016 (-22%)

CHOO:CNX $0.005 (0%)

CHOOF $0.003 (-16%)

CNBX $3.990 (0%)

CNGGF $0.203 (0%)

CODI $22.680 (0.22%)

CPMD $0.020 (-4.81%)

CRBP $0.281 (0.07%)

CRON $3.050 (0.33%)

CROP:CNX $0.015 (0%)

CSI:CNX $0.070 (-12.5%)

CURR $0.349 (2.65%)

CVSI $0.033 (7.49%)

DIGP $0.014 (0%)

EEVVF $0.078 (0%)

EMHTF $0.039 (10.17%)

EPWCF $0.059 (0%)

FFT:CNX $0.040 (0%)

FNNZF $0.075 (13.64%)

GNBT $0.001 (0%)

GRIN:CNX $0.075 (-16.67%)

GRWG $4.840 (-1.83%)

GTBIF $10.150 (-1.46%)

GTII:CNX $13.090 (-1.65%)

GWPH $218.960 (0%)

HEXO $0.196 (-0.56%)

HHPHF $0.079 (0%)

HLSPY $0.363 (0%)

HMLSF $2.800 (0%)

HMPPF $0.498 (0%)

HRVOF $0.023 (-11.07%)

HSTRF $0.135 (0%)

HUGE:CNX $1.180 (-1.67%)

IAN:CNX $0.075 (0%)

IGC $0.520 (-3.02%)

IGXT $0.219 (13.76%)

IIPR $92.910 (-2.5%)

INQD $0.009 (-3.23%)

IONC:CNX $0.005 (0%)

IONKF $0.005 (-2.04%)

ISOL:CNX $0.035 (0%)

ITHUF $0.062 (5.65%)

KBEV:CNX $0.045 (0%)

KHRNF $0.091 (-2.15%)

KSHB $0.695 (0%)

LHS:CNX $1.470 (0%)

LHSIF $1.145 (0%)

LXX:CNX $8.400 (0%)

MCIG $0.028 (0%)

MEDIF $0.057 (1.15%)

MGWFF $0.060 (9.57%)

MJ:CNX $0.050 (0%)

MJNA $0.015 (1.4%)

MNTR $0.040 (0%)

MYM:CNX $0.140 (0%)

MYMMF $0.106 (0%)

NCNNF $0.058 (0%)

NDVAF $0.111 (-6.17%)

Warning: Undefined array key 0 in /home/tech420/public_html/wp-content/themes/tech420/inc/shortcodes/stocks.php on line 51

Warning: Undefined array key 0 in /home/tech420/public_html/wp-content/themes/tech420/inc/shortcodes/stocks.php on line 52

NGW:CNX $0.410 (0%)

NRXCF $0.035 (0%)

NSPDF $0.010 (-23.53%)

NVTQF $0.596 (0%)

NWKRF $0.424 (0%)

NXGWF $0.316 (0%)

NXTTF $0.033 (6.61%)

OH:CNX $5.330 (0%)

ORHOF $4.050 (0%)

PHCG $0.001 (0%)

PHVAF $0.038 (0%)

PILL:CNX $0.230 (-17.86%)

PKG:CNX $0.020 (-20%)

PLPRF $0.357 (0%)

PLUS:CNX $0.440 (0%)

PMCB $2.420 (0%)

PNPL $0.012 (0%)

PTNYF $0.018 (3.24%)

QCA:CNX $0.095 (-5%)

RDDTF $0.020 (1.53%)

RLLVF $0.001 (0%)

RMHB $0.028 (2.8%)

RQB:CNX $0.005 (0%)

RQHTF $0.448 (2.99%)

SLNG:CNX $0.095 (-9.52%)

SMG $83.180 (-1.21%)

SNN:CNX $0.155 (0%)

SOL:CNX $0.320 (0%)

SOLCF $0.250 (0%)

SPLIF $0.016 (-15.79%)

SPRWF $0.268 (0%)

STEM:CNX $0.035 (0%)

STMH $0.028 (1.45%)

SUN:CNX $0.150 (0%)

TBPMF $0.052 (3.82%)

TCAN:CNX $0.135 (0%)

TCNAF $0.080 (0%)

TER:CNX $3.480 (-0.57%)

TGEN $1.200 (0%)

TGIF:CNX $0.025 (-16.67%)

TGIFF $0.020 (-12.28%)

THC:CNX $0.048 (0%)

THCBF $0.044 (12.85%)

TLRY $3.540 (1.14%)

TRLFF $0.035 (0%)

TRSSF $2.710 (0.37%)

TURV $0.001 (0%)

VIDA:CNX $0.055 (0%)

VIN:CNX $0.015 (0%)

VPRB $0.047 (-6%)

VRTHF $0.026 (0%)

VVCIF $0.035 (-8.14%)

WAYL:CNX $0.740 (0%)

XXII $1.740 (-12.12%)

ZDPY $0.740 (-2.63%)

ZYNE $1.190 (-0.83%)


Technical420’s Top Three Management Teams in the Cannabis Industry

Jun 2, 2015 • 4:39 PM EDT
6 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Investors need to be selective and do their due diligence prior to investing in a cannabis company. One of the most important factors than an investor needs to look into is the strength of the company’s management team. Technical420 has researched more than 200 cannabis companies and we have spoken with the management teams of such companies.

Which cannabis companies have the best management team?

Today, we want to highlight some of the strongest management teams in the cannabis industry. The companies we highlighted are GW Pharmaceuticals plc (GWPH), Mentor Capital, Inc. (MNTR), and Nemus Bioscience Inc. (NMUS)

GW Pharmaceuticals plc (GWPH)

Dr. Geoffrey Guy: In 1998, Dr. Geoffrey Guy founded GW Pharmaceuticals plc (GWPH) and has served as Chairman since then. Dr. Guy has over 30 years of experience in medical research and global drug development. In 1985, he founded Ethical Holdings plc and served as Chairman and CEO of the company. Under his leadership, Ethical Holdings (now known as Amarin Corporation plc) became listed on the NASDAQ.

In 2011, Dr. Guy was appointed as a visiting professor in the School of Science and Medicine at the University of Buckingham and received the “Deloitte Director of the Year Award in Pharmaceuticals and Healthcare”. Dr. Guy has been the physician in charge of over 200 clinical studies and is also an author of numerous scientific publications and a contributor to six books.

Dr. Guy holds a BSc. in pharmacology from the University of London, an MBBS at St. Bartholomew’s Hospital, an MRCS Eng. and LRCP London, an LMSSA Society of Apothecaries and a Diploma of Pharmaceutical Medicine from the Royal College of Physicians.

Justin Gover: Justin Gover has served as the CEO of GWPH since January 1999. He has 17 years experience in the pharmaceutical industry. Gover holds an M.B.A. from INSEAD and a BSc. (Hons) from Bristol University.

As CEO, Gover has been responsible for running GWPH’s operations. He has also led the company’s equity financings and business development activities. Prior to joining GWPH, Gover was Head of Corporate Affairs at Ethical Holdings plc from 1995 to 1997. At Ethical Holding, he was responsible for the company’s strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings, and investor relations.

Dr. Stephen Wright: Since 2004, Dr. Stephen Wright has been GWPH’s Director of Research and Development. Dr. Wright has more than 20 years experience in drug development.

Prior to joining GWPH, Dr. Wright was Senior Vice President of Clinical Research & Development and a member of the U.K. Board of Directors at Ipsen Limited, where he led teams responsible for regulatory success in both the United States and the European Union. Dr. Wright also has experience with United States drug development. He served as the Medical Director of Immunosciences and then as Venture Head of Neuroscience at Abbott Laboratories.

Dr. Wright received an M.D. and an M.A. in Social and Political Science from the University of Cambridge and qualified in Medicine (MBBS) at The Royal London Hospital. He is the author of more than 100 publications, and several book chapters.

Mentor Capital, Inc. (MNTR)

Chet Billingsley: Chet Billingsley is the CEO and chairman of Mentor Capital, Inc. In 1985, he formed Tech Start, the predecessor to Mentor Capital, in the heart of Silicon Valley and has held the general manager or president position since that time. In 1995, Billingsley took the firm public.

Billingsley did his undergraduate work at West Point and attended graduate school at Harvard University, receiving a Master’s degree in applied physics with concurrent study at Harvard Business School and at MIT studying proton radiology as applied to difficult to treat cancers; this was done in conjunction with Mass General Hospital.

Billingsley has never sold any shares of MNTR. He is ethical, intelligent, and strongly against pump and dump companies. 100% of his Mentor Capital shares are being held in a voluntary escrow at The Corporate Law Group in Burlingame, California. Chet’s shares may only be released back into his possession after a public announcement is made of the release.

Nemus Bioscience Inc. (NMUS)

John Hollister: NMUS is led by CEO John Hollister. Mr. Hollister received his BA in Economics from Stanford University and his MBA from Claremont University. He brings over 25 years of leadership experience to NMUS ranging from senior leadership positions at big pharma firms to start-ups.  His experience includes all facets of the product lifecycle from pre-human to phase IV management and leading cross-functional teams.  He has experience leading multiple pharmaceutical product launches at companies such as SmithKline Beecham and Amgen.

Dr. Brian Murphy: Dr. Brian Murphy, MD, MPH, MBA, is the company’s Chief Medical Officer. Dr. Murphy earned his MD, MPH, and MS degrees from New York Medical College and graduated from the Harvard School of Public Health. He earned his MBA at the Columbia University Graduate School of Business. Dr. Murphy has more than 15 years experience in drug development and evaluation, from both an academic and industry perspective. He most recently served as the Chief Medical Officer of Eiger Biosciences. Dr. Murphy is board-certified in internal medicine. He completed his residency in internal medicine at Tufts-New England Medical Center and served as Chief Medical Resident in the Boston University program. Dr. Murphy went on to complete parallel fellowship tracks at Harvard Medical School, one in internal medicine/clinical epidemiology at Massachusetts General Hospital and the other in medical ethics addressing issues of distributive justice and access to care.

Elizabeth Berecz: Elizabeth Berecz serves as the company’s Chief Financial Officer. She received her BA in Economics from Stanford University and a MA in Sports Management from University of San Francisco. Elizabeth is a seasoned financial executive with over 20 years experience holding senior level positions in both private and public companies. She started her career at Price Waterhouse in Silicon Valley where she spent five years auditing several high profile public companies in the technology industry. She then spent 10 years holding key leadership positions in a number of publicly held companies including Quantum Corporation, Business Objects, and Excite.

Douglas Ingram: Douglas Ingram, former President of Allergan Inc., serves as the Vice Chairman of NMUS’s Board of Directors. Ingram also agreed to serve as the Chair of the Compensation and Compliance Committee of the Board of Directors. Ingram brings nearly 20 years of pharmaceutical leadership experience to the company’s board. During his tenure as President of Allergan, Mr. Ingram led a team that effected a major restructuring of the company, reducing expenses by over $500 million dollars while driving enhanced sales and earnings growth, all of which significantly improved the market capitalization of the company. Prior to joining Allergan, Mr. Ingram was an attorney at Gibson, Dunn & Crutcher LLP from 1988 to 1996. Mr. Ingram received his Juris Doctorate from the University of Arizona in 1988.


Important Investor Disclosures:

Technical420 LLC is not a FINRA member firm. Technical420 LLC is responsible for the preparation and distribution of research created in the United States. Technical420 LLC is located at 40 SW 13th St. Suite 1002, Miami, FL 33130.

Technical 420 LLC, and any of its directors, officers, employees, affiliates, or subsidiaries does not accept any form of compensation from companies in return for writing reports on them. Also Technical 420 LLC, and any of its directors, officers, employees, affiliates, or subsidiaries do not hold any stock positions in companies covered by Technical420LLC.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Technical420 newsletter.

 All good -- no spamming here.